Mirae Asset Emerging Bluechip Fund - Regular fund ; a consistent performer !

Even as there are reports of equity markets being overvalued and index  (Nifty) PE touching 23, the momentum in the markets suggests the prices can inch further up and the new highs could well be reached very soon for Large cap index such as Sensex and Nifty. Whether the rally is liquidity driven or fundamentally driven or whether the investors are betting on 17 per cent EPS growth for Sensex stocks, whatever could be the reason for recent rally in the markets, the Mid cap indices have been rocking the markets by hitting all time highs. 

Within the mid cap space, Mirae Asset Emerging Bluechip Fund- Regular,  is one fund which has been a star performer and a consistent performer for several years put together. 

The fund has delivered a stellar 23.77 per cent CAGR return  over a 5 year period. The returns for 3 year period is 38.83 per cent on annualised basis, reflecting the best in class performance. The 1 year return for the fund has been 11.23 per cent; whereas the YTD performance has been 6.38 per cent. Return since launch for the fund is 22.51 per cent, with the launch date being July 2010. 

The benchmark for the fund is Nifty Free Float Mid Cap 100. The fund focuses on Medium capitalisation stocks with above average growth possibility. 

The fund with an expense ratio of 2.45 per cent has 10.36 per cent allocation to the giant or blue-chip stocks from various sectors , 19.67 per cent allocation to the large cap stocks and 58.39 per cent allocation to the Mid Cap stocks with 11.58 per cent being allocated to the small cap stocks. 

The fund with total assets under management  of Rs 1,623 crore has maximum exposure to the Financial sector at 21.68 per cent, followed by Services sector at 11.61 per cent, Healthcare sector at 10.91 per cent, Chemicals sector at 9.93 and Engineering sector at 8.81 per cent. 

The top 5 holdings of  the fund are Kotak Mahindra Bank (3.94 per cent), IndusInd Bank (3.84 per cent), HPCL (3.74 per cent), Exide Industries (3.08 per cent) and Torrent Pharmaceuticals (3.07 per cent).